MDGL (Madrigal Corp) Earnings growth in current year

MDGL (Madrigal Corp) - company brandmark

The annual earnings per share trend demonstrates the first-mover status of Madrigal Pharmaceuticals (MDGL) in NASH therapy, creating a monopoly patient base. However, geopolitical risks complicate international trials and component logistics. Growing competition in liver treatment threatens future price reductions. The value of 83.90 reflects the latest metric value, capturing the impact of margins and share buybacks on yield.

MDGL: Madrigal Pharmaceuticals Earnings per share growth in current year 07/04/2022 - 11/17/2026

Financial and market metric breakdowns for Madrigal Pharmaceuticals Inc (MDGL)

- share price and expert price forecast:
Basic company analysis:MDGL - Madrigal Corp
Finished products of Madrigal Pharmaceuticals, Inc.

This indicator measures the annual growth of net income per share, allowing for a comparison of the business's operational efficiency against market volatility and the macroeconomic backdrop. By analyzing the year-over-year growth rate of net income per share, investors assess the financial stability of the biotech sector, where the success of Madrigal Pharmaceuticals (MDGL) depends on clinical trials conducted with minimal environmental impact from laboratories.

Main competitors

ASND: Net earnings per one share growth for the current year|CORT (Corcept Therapeutics Corp) - Earnings growth in current year|Earnings growth in current year Rhythm Pharmaceuticals|Earnings growth in current year AKRO|Earnings per share growth in current year MTSR (Metsera, Inc.)|Earnings per share growth in current year moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth rate in current year|NAMS - Earnings per share growth in current year|SLNO: Earnings per share growth in current year|FOLD: Earnings growth in current year|ETNB - Expected net earnings per share growth this year|Earnings per share growth in current year Agios Corp|Structure Corp (GPCR) - Expected net earnings per share growth this year|Earnings per share growth in current year mimedx.com (MDXG)|Net earnings per share growth this year rezolutebio.com RZLT|Earnings per share growth in current year Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Earnings per share growth in current year|ALT: Net earnings per share growth this year|AARD - Earnings growth in current year|SGMT: Earnings growth in current year|Earnings per share growth rate in current year BioAge Labs, Inc. (BIOA)|Earnings per share growth in current year Biomea Fusion Inc|Earnings per share growth this year QNCX (Quince Therapeutics)|Net earnings per share growth this year GUTS (Fractyl Health)|Net earnings per one share growth for the current year VTVT|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year